source
- GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA reviewGSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and…
- Grace Science warns FDA bottleneck threatens ultra-rare gene therapy progressGrace Science, a biotech focused on ultra-rare diseases, has been developing a gene-therapy candidate that appeared close to regulatory approval. The company, co-founded by Nobel laureate Carolyn…